Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer With Ritu Salani, MD, MBA, and Floor J. Backes, MD

Oncology Data Advisor™ · Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States (ACS, 2022). The mortality rate has increased approximately 1% each year from 2015 to 2019, an increase which may be related to a higher rate of advanced-stage ca...

Continue reading

FDA Grants Regular Approval to Pembrolizumab/Lenvatinib Combination for Endometrial Carcinoma

The FDA has granted regular approval to pembrolizumab (Keytruda®, Merck), in combination with lenvatinib, (Lenvima®, Eisai), for patients with advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. Prior to this regular approval, the FDA granted accelerated approval to the pembrolizumab/lenvatinib co...

Continue reading

Dostarlimab-gxly Approved for Recurrent/Advanced Endometrial Cancer

The FDA has granted accelerated approval to dostarlimab-gxly (Jemperli®, GlaxoSmithKline) for patients with mismatch repair deficient recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing chemotherapy. "The prognosis for patients with a diagnosis of advanced or recurrent endometrial cancer is poor, and, to our knowledge, there are no accepted consensus-based guidelines for standard of care after the disease progresses while undergoing or after treat...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.